Rethinking Drug Pricing and Market Behavior

For a long time, pharmaceutical executives have claimed that drug pricing is largely beyond their control. They often point to government regulations, research expenses, and reimbursement policies as the reasons why Americans pay significantly more at pharmacies compared to other countries with advanced economies.

This narrative is somewhat clean and easy to digest, but it’s also only partially accurate—pharmaceutical companies could indeed lower their prices. However, various governmental factors have created conditions where there’s little incentive for them to do so.

In a well-functioning market, companies usually set prices based on what consumers are willing to pay. Typically, those prices decrease over time due to innovation and competition. Yet, in certain sectors like housing, education, and health care, the opposite trend seems to prevail, often due to governmental influence.

In pharmaceuticals, several dynamics work against competitive pricing. To illustrate, U.S. taxpayers fund about $17 billion annually for initial research and clinical trials, while companies price their products as if they bear all those costs alone. In other markets, such substantial subsidies would likely lead to lower prices, but in this case, the opposite occurs.

Additionally, there’s a form of guaranteed demand created by government policies. Institutions like schools and the military require vaccinations, and federal programs cover millions of prescriptions. These aren’t competitive settings; they’re somewhat compelled markets where suppliers don’t face significant risks regarding losing substantial customer bases.

When demand is assured through federal or state policies, companies have less motivation to keep prices competitive. A market where participants can’t walk away tends to see higher costs.

Compounding this issue is patent exploitation, where pharmaceutical firms extend patents on essential medications repeatedly, often far beyond reasonable limits, which can make treatments unaffordable for many patients.

Most industries lack this combination of subsidized research and assured large-scale buyers. For instance, a restaurant chain cannot depend on government funds for initial growth, nor can a tech startup demand that schools procure its software. Airlines can’t assume that government agencies will always be their guaranteed customers without options.

These sectors operate under conditions where pricing is influenced by consumer choice and competitive pressures.

Ironically, pharmaceutical companies are acting precisely as economic theory would suggest. Students often bemoan rising college costs—yet, they continue to climb due to government loans and scholarships that inject vast sums as long as students are willing to “sign on the dotted line.”

Similar situations arise in housing. Government initiatives aimed at promoting homeownership have created problematic incentives for both lenders and buyers, evidenced by the 2007 financial crisis when these bubbles burst.

The issue isn’t that companies are following incentives. The trouble lies in the fact that the incentives in the pharmaceutical market are skewed by public policy decisions that favor one side.

The takeaway for policymakers and the public is pretty clear. If we desire a drug market to function like a true market, we need to construct one that aligns research incentives with affordability and reevaluates mandates that ensure revenue without accountability.

Ultimately, a company’s primary responsibility is to its shareholders. If the market structure allows for price increases, reduced competition, or protected revenues, it’s to be expected that the firm will seek those benefits.

While there’s nothing wrong with firms aiming for profit, there is something amiss with a system that protects them from the competitive dynamics that keep other industries in check.

When companies claim they cannot reduce prices, it often indicates they simply choose not to. Prices are influenced by decisions from all players in the market, including consumers, manufacturers, and regulatory bodies.

Recognizing that prices are not immutable could lead to a change where Americans no longer bear the burden of a pharmaceutical system that suggests the opposite.